Abpro Holdings, Inc.

Abpro Holdings, Inc. (ticker: ACAB) is a clinical-stage biopharmaceutical company that entered the U.S. public equity markets through a special purpose acquisition company merger. Focused on next-generation antibody engineering, the company develops therapeutic candidates across oncology and immunology indications. As an active post-merger reporting issuer in the life sciences sector, Abpro Holdings filed a Form 10-Q with the Securities and Exchange Commission on July 9, 2024, continuing its periodic disclosure obligations as a publicly traded entity. Investors and analysts tracking SPAC-origin biotech companies can explore the full filing history, sponsor details, and deal metrics for ACAB by signing up for complete data on SpacDesk.